Mologic

British diagnostics developer Mologic announced Monday that it plans to transform from a for-profit company into a social enterprise through an acquisition worth at least $41 million. The Soros Economic Development Fund is leading the takeover with support from the Gates Foundation, according to Mologic’s press release.

Under a new name—Global Access Health—the firm aims to expand affordable access to medical technology in LMICs, including tests for diseases such as bilharzia, Covid-…


The state of the hunt: 

Novavax became the biggest recipient of CEPI funds for Covid-19 this week, with a new $384 million award for its recombinant protein vaccine candidate. CureVac’s mRNA vaccine candidate induced high levels of virus-neutralizing titers at a low dose in preclinical studies. Gilead announced voluntary royalty-free licenses for remdesivir with five generic drug manufacturers, and more may be in the works.
 

 

Vaccines

Our Covid-19…

As the United States eclipsed China in confirmed cases, more vaccines neared human trials and funders made over $330 million in new commitments to fight Covid-19.

The week’s noteworthy developments included:

Vaccines

On vaccines, the University of Oxford announced today that it has begun recruiting volunteers for clinical trials—set to begin in weeks—of ChAdOx1 nCov-19, its adenovirus vector-based shot.

Sanofi announced today a collaboration with Massachusetts…

Progress continued on vaccines, treatment and tests for Covid-19 over the past week as WHO declared the disease a pandemic and funders announced more grants.

Vaccines

On vaccines, the Coalition for Epidemic Preparedness Innovations (CEPI) announced two new grants this week: $4 million supporting Novavax’s use of recombinant protein nanoparticle technology to develop vaccine candidates, and a smaller amount to fund the University of Oxford’s candidate search using its…

France nonprofit Bioaster announced this month that the Gates Foundation is awarding it $885,000 to develop a field-appropriate rapid test for onchocerciasis. According to the company press release, Bioaster will partner with UK-based diagnostic specialist Mologic on a prototype for the high-specificity detection of O. volvulus antibodies in human blood.